Abstract:e15702 Background: Incidence of pancreatic cancer has been significantly increasing over the years and likely to become 2nd most common cause of caner death as early as 2020. One of main reasons for the high mortality rate of pancreatic cancer is the lack of sensitive and specific tools to detect in early stages. Developing an effective and credible assay platform will fill an unmet need in cancer screening and early detection. We have recently demonstrated, in two blinded independent clinical studies, the clinical utility and performance of Electric Field Induced Release and Measurement (EFIRM)-based detection of actionable EGFR mutations in plasma and saliva from non-small cell lung carcinoma (NSCLC) patients with near 100% concordance with tissue biopsy-based genotyping. We hypothesize this novel and biopsy-concordant technology is translatable to the detection/risk assessment of pancreatic ductal adenocarcinoma (PDAC). Methods: We have developed EFIRM probes for the top four KRAS mutations (G12D, G12V, G12R and G12C with > 90% frequency in total) associated with PDAC. Detection efficiency of probes for mutated KRAS was verified and optimized and subsequently tested with genomic DNA harboring a respective mutation. Results: EFIRM KRAS probes were designed and efficiency in detecting a single base KRAS mutation was optimized by utilizing synthetic oligo DNAs. Specificity and sensitivity has been further optimized by hybridization conditions, particularly by applying different electric potentials. EFIRM KRAS mutation assay efficiently differentiated a single point KRAS mutation from a wild type in sheared cellular genomic DNA harboring each of the four KRAS mutations. EFIRM is a novel detection platform ready for clinical verification to detect KRAS mutations in resectable PDAC plasma/serum samples with matched tissues. Conclusions: We have developed novel EFIRM cell free DNA KRAS assays that has a promising clinical utility as a credible, sensitive and noninvasive clinical tool in screening the patients for endoscopic evaluation and for potential prognostic/management of PDAC.

Electrochemical Detection of BRAF V600E Mutation in a Liquid Biopsy Format: LAMPing the Way to an Improved Diagnostics and Treatment

Single-molecule detection of cancer mutations using a novel PCR-LDR-qPCR assay

Innovative PNA-LB mediated allele-specific LAMP for KRAS mutation profiling on a compact lab-on-a-disc device

Combining the amplification refractory mutation system and high-resolution melting analysis for KRAS mutation detection in clinical samples

High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens

A More Sensitive Platform for the Detection of Low-Abundance Braf(V600e) Mutations

An Optimized CRISPR/Cas12a Assay to Facilitate the BRAF V600E Mutation Detection

Target Enrichment Enhances the Sensitivity of Sanger Sequencing for BRAF V600 Mutation Detection

Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA

Real-time detection of BRAF V600E mutation from archival hairy cell leukemia FFPE tissue by nanopore sequencing

Clinical Significance of BRAFV600E Mutation in Circulating Tumor DNA in Chinese Patients with Melanoma

The fluorescence amplification strategy based on 3D DNA walker and CRISPR/Cas12a for the rapid detection of BRAF V600E

Highly Sensitive Detection of Low-Abundance BRAF V600E Mutation in Fine-Needle Aspiration Samples by Zip Recombinase Polymerase Amplification

RLP system: A single-tube two-step approach with dual amplification cascades for rapid identification of EGFR T790M

ddPCR Overcomes the CRISPR-Cas13a-Based Technique for the Detection of the BRAF p.V600E Mutation in Liquid Biopsies

Single-Droplet Microsensor for Ultra-Short Circulating EFGR Mutation Detection in Lung Cancer Based on Multiplex EFIRM Liquid Biopsy

Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD)

Ultrafast and Highly Specific Detection of One-Base Mutated Cell-Free DNA at a Very Low Abundance

BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma

Clinical Validity of Electric Field Induced Release and Measurement (efirm) for Kras Mutation Detection in Circulating Dna Associated with Pancreatic Ductal Adenocarcinoma.

High Sensitivity Scanning of Colorectal Tumors and Matched Plasma DNA for Mutations in APC, TP53, K‐RAS, and BRAF Genes with a Novel DHPLC Fluorescence Detection Platform